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Background: Although colon cancer (CC) with microsatellite instability (MSI) has a more favorable prognosis than micro-
satellite stable (MSS) CC, the impact varies according to clinicopathological parameters. We studied how MSI status
affects prognosis in a trial-based cohort of stage II and III CC patients treated with 5-ﬂuorouracil (5-FU)/leucovorin or
FOLFIRI.
Materials and methods: Tissue specimens of 1254 patients were tested for 10 different loci and were classiﬁed as
MSI-high (MSI-H) when three or more loci were unstable and MSS otherwise. Study end points were overall survival (OS)
and relapse-free survival (RFS).
Results: In stage II, RFS and OS were better for patients with MSI-H than with MSS CC [hazard ratio (HR) 0.26, 95% CI
0.10–0.65, P = 0.004 and 0.16, 95% CI 0.04–0.64, P = 0.01). In stage III, RFS was slightly better for patients with MSI-H
CC (HR 0.67, 95% CI 0.46–0.99, P = 0.04), but the difference was not statistically signiﬁcant for OS (HR 0.70, 95% CI
0.44–1.09, P = 0.11). Outcomes for patients with MSI-H CC were not different between the two treatment arms. RFS
was better for patients with MSI-H than with MSS CC in the right and left colon, whereas for OS this was signiﬁcant only
in the right colon. For patients with KRAS- and BRAF-mutated CC, but not for double wild-type patients, RFS and OS
were signiﬁcantly better when the tumors were also MSI-H. An interaction test was statistically signiﬁcant for KRAS and
MSI status (P = 0.005), but not for BRAF status (P = 0.14).
Conclusions: Our results conﬁrm that for patients with stage II CC but less so for those with stage III MSI-H is strongly
prognostic for RFS and OS. In the presence of 5-FU treatment, stage II patients with MSI-H tumors maintain their survival
advantage in comparison with MSS patients and adding irinotecan has no added beneﬁt.
ClinicalTrials.gov Identiﬁer: NCT00026273.
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introduction
Approximately 15% of colon cancer (CCs) are characterized by
incompetence of the DNA mismatch repair (MMR) system,
leading to abnormal shortening or lengthening of repeating base
pair units of DNA, a phenomenon known as microsatellite in-
stability (MSI) [1]. In sporadic CC, MSI is largely due to MLH1
inactivation through hypermethylation of the promoter [2]. In
familial CC, MSI is mostly due to inherited germline mutation
of a MMR gene (notably MLH1 and MSH2) [3]. In sporadic
CC, MSI is more frequent in stage II (almost 20%) and III (12%)
tumors than in stage IV tumors (4%) [4].
Patients with MSI-Η tumors evolve more favorably than those
with MSS. Several retrospective studies [1, 5, 6], a meta-analysis
[7], and recent large trials [8–12] support the notion that stage-
adjusted prognosis is more favorable for MSI-H than for MSS
CC patients, but the difference in prognosis is larger for stage II
than for stage III patients.
According to the current guidelines, adjuvant chemotherapy is
the treatment of choice for stage III and a minority of high-risk
stage II patients [13]. Disease stage remains the key determinant
of prognosis and treatment, but more accurate prognostic and
†Previous presentations: Presented in part as oral presentation at the 45th Annual
Meeting of the American Society of Clinical Oncology, 29 May–2 June 2009, Orlando, FL,
USA.
‡Both authors contributed equally to this work.
*Correspondence to: Prof. Sabine Tejpar, Molecular Digestive Oncology Unit, Leuven
University Hospital, Herestraat 49, Leuven B-3000, Belgium. Tel: +32-16-34-42-25;
Fax: +32-16-34-44-19; E-mail: sabine.tejpar@uz.kuleuven.ac.be
original articles Annals of Oncology
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com.
predictive markers are urgently needed. MSI, 18q loss of hetero-
zygosity, KRAS, BRAF, and TP53mutations have been intensive-
ly investigated in this context [4, 14–16], but most are not
incorporated into the treatment guidelines nor have they been
confronted in large series to traditional stage II high-risk fea-
tures [13] or to more recent gene expression-based prognostic
signatures [17].
A putative predictive role of MSI for response to 5-ﬂuoroura-
cil (5-FU)-based adjuvant chemotherapy has been a more con-
tentious issue. Some reports have suggested that disease
outcome after chemotherapy does not differ between patients
with MSI-H and MSS CC [18], whereas others showed increased
sensitivity to 5-FU for the patients with MSI-H CC [19]. Data
from randomized clinical trials of 5-FU-based therapy versus
surgery only, however, suggested that patients with MSI-H CC
do not beneﬁt from 5-FU-based adjuvant chemotherapy com-
pared with surgery-alone [6]. This was conﬁrmed in a pooled
analysis [10], which added 457 cases to the previously published
570 [6]. In a recent study, however, the survival beneﬁt of stage
III MSI-H CC patients was maintained under 5-FU [11].
An issue remains the impact of MSI on the choice of adjuvant
therapy. One trial initially suggested a differential effect of irino-
tecan-based adjuvant chemotherapy (CALGB 89803) in favor of
MSI-H patients [20], but this became marginal in an updated
report [8].
To clarify these controversies, we studied stage-speciﬁc prog-
nostic effects of MSI in the homogeneous PETACC-3 trial colon
cancer population treated with 5-FU or FOLFIRI. The key ques-
tion was whether patients with MSI-H CC maintain their sur-
vival beneﬁt under 5-FU treatment, when stratiﬁed for stage and
treatment. In addition, we investigated how tumor site, BRAF
and KRAS status, and high-risk stage II factors modulate the
prognostic effect of MSI.
patients andmethods
patient characteristics
All eligible patients were randomly assigned to receive 6 months of either
5-FU/leucovorin (LV) alone or with irinotecan [21]. MSI status could be
determined for 1254 of the 1564 patients of whom tissue was available for
analysis (89%), out of the total trial population of 3278 patients [14]. Earlier
reports describe how further molecular parameters (p53 expression,
SMAD4 expression, 18q LOH, BRAF, and KRAS mutation status) were
obtained [4, 14, 15]. End points were overall survival (OS), deﬁned as the
time from randomization until death, and relapse-free survival (RFS),
deﬁned as the time from randomization to local, regional, or distant relapse,
the occurrence of a second primary colon cancer or death.
MSI determination
MSI was evaluated at 10 different microsatellite loci containing mono- or di-
nucleotide repeated sequences. The panel consisted of the ﬁve markers from
the Bethesda reference panel, with the addition of ﬁve markers which were
also suggested during the International Workshop on HNPCC in 1997
(BAT-25, BAT-26, D2S123, D5S346, TGFBR2, BAT-40, D17S787, D18S69,
D17S250, and D18S58) [22]. The ampliﬁed PCR products were analyzed
using the automated ABI Prism Sequencer Model 3100 Genetic Analyzer
(Applied Biosystems, Foster City, USA). A locus was called unstable if un-
equivocal instabilities were seen in the tumor sample in comparison with the
paired normal DNA of the same patient. MSI was graded as high (MSI-H)
when three or more markers were unstable, low (MSI-L) when one or two
markers were unstable, and stable (MSS) when all markers were stable. For
analysis, MSI-L and MSS populations were pooled to MSI-L/S.
The determination of the other markers has been described before [4, 14, 15].
statistical analyses
Survival curves were determined using Kaplan–Meier methods and com-
pared using the log-rank test. Frequencies were compared using Fisher’s
exact and Pearson’s χ2 tests. Continuous variables were compared by MSI
status using Wilcoxon’s rank sum test. Hazard ratios (HRs) with 95% conﬁ-
dence intervals (CIs) were computed with uni- and multivariable propor-
tional hazard models. Interactions were assessed by likelihood ratio tests.
P-values are two-sided, not adjusted for multiple testing, and considered sig-
niﬁcant if <0.05. Analyses were carried out using the free R software package
(www.r-project.org) version 2.13.0 or later.
results
patient and tumor characteristics in relation
to MSI status
Patients and tumor characteristics by MSI status are summar-
ized in Table 1. The MSI-H frequency was almost twice as high
in node-negative, compared with node-positive, patients. The
proportion of MSI-H tumors was higher with higher T-stage, in
the right colon, when poorly differentiated, mutated for BRAF
or with high thymidylate synthase (TYMS) expression, but
lower for mucinous tumors and those with SMAD4 loss, high
TP53 expression and (weakly) a KRASmutation.
prognostic value of MSI varies according to stage
After a median follow-up of 69.1 months, RFS (HR 0.48, 95%
CI 0.34–0.69, P < 0.001) as well as OS (HR 0.47, 95% CI 0.31–
0.72, P < 0.001) were better for patients with MSI-H than with
MSI-L/S CC. This was most striking in patients with stage II CC
with a strong effect of MSI status on RFS and OS, still signiﬁcant
but weaker for RFS in stage III patients but not signiﬁcant for
OS in stage III (Figure 1A and B). A statistically signiﬁcant inter-
action between stage and MSI status was found for OS
(P = 0.047), still borderline signiﬁcant for RFS (P = 0.06).
the prognostic value of MSI is not affected by 5-FU/
LV versus FOLFIRI treatment
For stage II 5-FU/LV- as well as FOLFIRI-treated patients, RFS
and OS were better for MSI-H than for MSI-L/S CC (Figures 1C
and D, and 2).
For stage III 5-FU/LV-treated patients, the MSI-H effect was
weaker compared with stage II 5-FU/LV-treated patients. For
stage III FOLFIRI-treated almost no difference was found by
MSI status, neither on RFS nor on OS (Figures 1E and F, and 2).
An interaction test between treatment and MSI status within
stage III patients, however, was not signiﬁcant (P = 0.31 for RFS
and P = 0.18 for OS).
When patients were stratiﬁed according to MSI status, RFS
and OS were similar in both treatment arms. We could not
conﬁrm the beneﬁt suggested by Bertagnolli et al. [8] for irinote-
can addition in MSI-H tumors (supplementary Table S1, avail-
able at Annals of Oncology online).
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MSI is prognostic in both the right and left colon
Right-sided carcinomas were almost ﬁve times more often MSI-
H than left-sided carcinomas. More precisely, we found a
gradual pattern of MSI-H incidence as reported elsewhere [23].
RFS was better for patients with MSI-H than for MSI-L/S CC,
regardless of side. In the right colon, OS was statistically signiﬁ-
cantly different between MSI-H and MSI-L/S CC, but not in the
left. Of note is the similarity of the two HRs (Figure 2), with a
non-signiﬁcant interaction. As left CCs are less frequently MSI-
H than right CCs (n = 46versus 144), the power of tests in this
subgroup is lower.
For patients with a stage II carcinoma in the left colon, RFS was
similar for MSI-H and MSI-L/S CC, whereas in the right colon,
RFS was signiﬁcantly better for patients with MSI-H CC. For
patients with stage II carcinomas in the left colon, MSI status had
no effect on OS. There was no event for the 64 MSI-H CC in the
right colon. For stage III patients, RFS and OS tended to be better
for MSI-H carcinomas, irrespective of site, but this trend was not
signiﬁcant. These observations were conﬁrmed in multivariable
models including BRAFmutation status and gender.
MSI status and BRAF/KRAS status
BRAF-mutated CCs were almost four times more often MSI-H
than BRAF wild-type CC. In contrast, KRAS-mutated CCs were
1.5 times less often MSI-H than KRAS wild-type CC (Table 1).
In patients with a double wild-type CC, MSI status had no effect
on RFS or OS (Figure 2). For patients with a KRAS-mutated CC,
however, RFS and OS were clearly better. An interaction test for
KRAS and MSI status was signiﬁcant (P = 0.005). For BRAF-
mutated carcinomas, the CIs were larger, but the effect was still
signiﬁcant for both RFS and OS. A test for interaction between
MSI and BRAF status, however, was not signiﬁcant (P = 0.14).
Conversely, BRAF status was not prognostic in patients with a
MSI-H CC (RFS: HR = 1.26, 95% CI 0.59–2.70, P = 0.55; OS:
HR = 1.53, 95% CI 0.63–3.70, P = 0.35). Similar results were
obtained in multivariable analyses when stratiﬁed by stage (sup-
plementary Table S2, available at Annals of Oncology online).
MSI status and stage II risk factors
As shown in supplementary Table S3, available at Annals of
Oncology online, the distribution of MSI-H and MSI-L/S
according to stage II risk factors was similar in both groups,
except for poorly differentiated CC, which are rare (5.3% of all
stage II tumors) but more often MSI-H. Small patient numbers
allowed only univariate analyses of these risk factors in the MSI-
H group. T stage (HR = 5.28, 95% CI 0.88–31.64, P = 0.07), posi-
tive margins (HR = 11.53, 95% CI 1.28–104.15, P = 0.03), and
perforation (HR = 8.40, 95% CI 1.40–50.38, P = 0.02) were prog-
nostic but with high uncertainty due to small patient numbers.
When combining risk factors into a high-risk group with at
least one risk factor and a low-risk group without any risk
factor, the HRs of patients with MSI-L/S CC were higher than
those of high-risk patients both in RFS (HR = 3.63, 95% CI
1.46–9.04, P = 0.006 versus HR = 2.40, 95% CI 1.28–4.47,
P = 0.006) and OS (HR = 6.03, 95% CI 1.46–24.91, P = 0.01
versus HR = 2.80, 95% CI 1.25–6.28, P = 0.01). This suggests
that the prognostic value of MSI status is stronger than that of
the combined classical risk factors for stage II patients. In a
Table 1. Association between MSI status, patients’ characteristics,
and tumours’ molecular characteristics
Patients’ and molecular
tumors’ characteristics
MSI-L/S patients
n (%)
MSI-H
n (%)
P-value
Total number of cases
(n = 1254)
1064 (84.9) 190 (15.1)
Stage
II 309 (78.2) 86 (21.8) <0.001
III 755 (87.9) 104 (12.1)
Treatment group
5-FU/FA 533 (84.2) 100 (15.8) 0.53
FOLFIRI 531 (85.5) 90 (14.5)
N-stage
N0 309 (78.2) 86 (21.8) <0.001
N1 495 (88.4) 65 (11.6)
N2 260 (87.0) 39 (13.0)
T-stage
T1/2 69 (93.2) 5 (6.8) 0.03
T3 815 (85.1) 143 (14.9)
T4 180 (81.1) 42 (18.9)
Grade
G-1/2 993 (87.8) 138 (12.2) <0.001*
G-3/4 63 (55.3) 51 (44.7)
No result 8 1
Mucinous features
Yes 898 (88.6) 115 (11.4) <0.001*
No 158 (68.1) 74 (31.9)
No result 8 1
Primary tumor location
Left 707 (93.9) 46 (6.1) <0.001
Right 357 (71.3) 144 (28.7)
SMAD4 expression status
No loss 799 (81.8) 178 (18.2) <0.001*
Any loss 249 (95.8) 11 (4.2)
No result 16 1
BRAFmutation status
Wt 1002 (87.5) 143 (12.5) <0.001*
mut 53 (54.6) 44 (45.4)
No result 9 3
KRASmutation status
Wt 626 (83.0) 128 (17.0) 0.03*
mut 421 (87.7) 59 (12.3)
No result 17 3
TP53 expression status
≤45% cells positive 641 (78.7) 173 (21.3) <0.001*
>45% cells positive 410 (96.5) 15 (3.5)
No result 13 2
TYMS expression status
>75% cells positive 254 (67.7) 121 (32.3) <0.001*
<75% cells positive 708 (92.2) 60 (7.8)
No result 102 9
Age, median (range) 61 (21–76) 54 (25–75) <0.001
MSI, microsatellite instability; MSI-L/S, MSI-low/stable, MSI-H,
MSI-high; TYMS, thymidylate synthase.
*Missing values have not been considered for the calculation of
P-values. Except for TYMS expression, there was no significant
difference in terms of missingness between MSI-H and MSI-L/S
tumors.
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Figure 1. Kaplan–Meier plots showing outcome according to tumor stage, treatment, and microsatellite status. (A) Relapse-free survival (RFS), (B) overall
survival (OS), (C) RFS in stage II, (D) OS in stage II, (E) RFS in stage III, (F) OS in stage III. SII, stage II; SIII, stage III; MSI, microsatellite instable; MSI-H,
MSI-high; MSI-L/S, MSI-low/stable.
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multivariable model, T stage alone was stronger than all other
risk factors combined and equaled the effect of MSI status (sup-
plementary Figure S1 and Table S4, available at Annals of
Oncology online).
discussion
Our results conﬁrm earlier reports [1, 5–8, 10, 18] that MSI-H
colon cancer patients have a better survival than those with
MSI-L/S tumors (supplementary Table S5, available at Annals of
Oncology online). Furthermore, we conﬁrm MSI-H tumors to be
more often stage II, located in the proximal colon, and of poor
or undifferentiated histology, in line with previous reports [8,
10, 11, 24].
We found the MSI-H effect on RFS and OS to be stronger in
stage II than in stage III patients [9]. The striking effect in stage
II, even though in both arms patients were treated with 5-FU,
suggests that patients with MSI-H tumors have a good progno-
sis, even when treated. Earlier work of Sargent et al. [10] has
suggested a lack of beneﬁt from 5-FU-based chemotherapy, but
in the absence of an untreated control arm, however, our dataset
cannot assess directly the effect of 5-FU on MSI-H patients.
Furthermore, we have shown that MSI-H colon cancer
patients treated with FOLFIRI do not fare better than those
treated with only 5-FU/LV [12], in contrast to an earlier report
of Bertagnolli et al. [20]. More in line with our data, Bertagnolli
et al. [8] recently reported, in a larger patient cohort, an only
marginally signiﬁcant increase in RFS for 5-FU-/irinotecan-
treated MSI-H patients, when all other risk factors were taken
into account. We found no evidence for stage-speciﬁc or overall
interactions between treatment and MSI status. Nevertheless, in
the above-mentioned two trials, different irinotecan-based regi-
mens were used. These differences must be taken into consider-
ation in cross-trial comparisons.
We conﬁrm the high frequency of BRAF mutations in the
MSI-H population [25]. As a novel observation, we ﬁnd MSI to
be prognostic in KRAS- and BRAF-mutated, but not in double
wild-type, patients. BRAF, however, had no prognostic impact
in MSI-H patients, possibly limited by sample size [26].
A still unanswered question involves the potential impact of
the site of the primary tumor, for which we report novel data on
the PETACC3 cohort. We found no difference in RFS, between
right- and left-sided MSI-H carcinomas. OS of patients with a
right-sided MSI-H CC was signiﬁcantly better compared with
those with a right-sided MSI-S/L CC, as previously reported
[27]. Our data, however, do not provide convincing evidence in
favor of or against a beneﬁt for patients with a left-sided MSI-H
CC. In a recent publication, Sinicrope et al. [28] reported that,
although patients with a MSI-H right-sided CC have a statistic-
ally signiﬁcant DFS advantage, the outcome of those with a left-
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Figure 2. Forest plots of the prognostic value of MSI status in selected patient groups. RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; 95%
CI, 95 percent conﬁdence interval; SII, stage II; SIII, stage III; wt, wild type; mut, mutated.
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sided MSI-H CC was worse, which we did not ﬁnd. A larger val-
idation series is needed to settle this question, especially given
the evidence for stage-speciﬁc effects. The improvement in RFS
and OS for stage II patients with a MSI-H CC seemed stronger
in the right than in the left colon, with the notable observation
that out of 64 patients not a single patient with a stage II right-
sided MSI-H CC had died and only three had relapsed. Such
differences were not found in stage III patients. Another hypoth-
esis emerging from our data, but in need of validation, is the
potential interaction between KRASmutation and MSI status.
An open issue is how useful MSI status is as a marker for stage
II patients considered for 5-FU chemotherapy. We compared MSI
status with conventionally applied high-risk factors [29]. In terms
of RFS and OS, MSI-H status was slightly stronger than the com-
bination of high-risk factors. Among high-risk factors, T-stage was
the strongest. Comparison between T-stage and MSI status
resulted in a similar effect on outcome, as we previously reported
[15]. Previously published data from the Sargent group [10, 30]
advocated that MSI-H patients might be spared adjuvant treat-
ment. The lack of untreated patients in our study prevents a direct
comparison, but we found that stage II patients with T3 and MSI-
H CC fare very well. Given the modest treatment effect of 5-FU in
this population, they seem to represent the best candidate group
for omitting adjuvant treatment. Conversely, patients with MSI-S/
L T4 CC fared much worse, even though they received chemother-
apy. For the intermediate-risk patient with a MSI-H T4 or a MSI-
S/LT3 CC, other factors need to be considered before a conclusion
can be reached.
In conclusion, our results conﬁrm that MSI-H is strongly
prognostic for RFS and OS for stage II patients, and less so for
stage III patients. In the presence of 5-FU treatment, stage II
patients with MSI-H tumors maintain their survival advantage
in comparison with MSI-L/S patients and adding irinotecan has
no added beneﬁt. Additional parameters (including gene expres-
sion proﬁling, ploidy, methylation, and microRNA expression)
have to be explored in order to more accurately deﬁne stage II
patients who require adjuvant treatment and to predict which
patients will respond. Based on new emerging information,
further exploratory analyses in large patients’ cohorts looking
also at the impact of site, mutation proﬁle, and genomic signa-
tures will be necessary to further appreciate the molecular and
prognostic impact of MSI status in colon cancer.
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Abituzumab combined with cetuximab plus irinotecan
versus cetuximab plus irinotecan alone for patients
with KRASwild-type metastatic colorectal cancer:
the randomised phase I/II POSEIDON trial
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Background: Integrins are involved in tumour progression and metastasis, and differentially expressed on colorectal
cancer (CRC) cells. Abituzumab (EMD 525797), a humanised monoclonal antibody targeting integrin αν heterodimers,
has demonstrated preclinical activity. This trial was designed to assess the tolerability of different doses of abituzumab in
combination with cetuximab and irinotecan (phase I) and explore the efﬁcacy and tolerability of the combination versus
that of cetuximab and irinotecan in patients with metastatic CRC (mCRC) (phase II part).
Methods: Eligible patients had KRAS (exon 2) wild-type mCRC and had received prior oxaliplatin-containing therapy.
The trial comprised an initial safety run-in using abituzumab doses up to 1000 mg combined with a standard of care
(SoC: cetuximab plus irinotecan) and a phase II part in which patients were randomised 1 : 1 : 1 to receive abituzumab
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